查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1371926

到 2030 年动脉粥状硬化市场预测：按类型、治疗方法、给药途径、通路、诊断、最终用户和地区进行全球分析

Atherosclerosis Market Forecasts to 2030 - Global Analysis By Type, Treatment, Route of Administration, Distribution Channel, Diagnosis, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，预测期内全球动脉粥状硬化市场的年复合成长率为 4.24%。

动脉粥状硬化是一个术语，用于描述由动脉内的胆固醇斑块引起的动脉逐渐硬化和积聚。治疗高血压和高胆固醇的药物即使无法阻止动脉硬化，也可以减少动脉硬化。这可以降低心臟病发作和中风的风险。搭桥手术使用来自身体其他部位的血管或合成管来绕过阻塞或狭窄的动脉。溶栓疗法是将药物注射到受影响的动脉中以溶解血栓的治疗方法。斑块旋切术是治疗方法使用一端带有刀片的导管去除动脉斑块的治疗方法。

根据欧洲心臟网路统计，欧洲每年有390万人罹患心血管疾病，超过180万人死亡。

心血管疾病患病增加

由于全球心血管疾病发生率的增加，预计该市场将发展得更快。由于久坐的生活方式，已开发国家心血管疾病的发生率最高。此外，老年人口的增加、久坐的生活方式导致心血管疾病的发病率更高，以及对现有治疗方法的认识不断增强，预计将推动所研究的市场。

与动脉硬化相关的副作用

动脉粥状硬化会增加心臟病和中风等心血管事件的风险。这些事件可能导致死亡或严重残疾。周边动脉疾病可能是由四肢（尤其是腿部）动脉粥状硬化引起的。这可能会导致不适、麻木和行走困难。这会降低动脉的弹性并增加血压，从而对心血管系统带来更大的压力。预计市场成长将受到动脉粥状硬化和低疗效的不利影响的阻碍。

增加医疗保健基础设施支出

增加医疗保健支出有助于加强基础设施，是推动市场成长率的因素。随着资金的增加，许多政府机构正在寻求加强其医疗基础设施。政府和私人机构提高意识提升、增加可支配所得和高血压发病率是预计在整个预测年度推动市场成长率的其他关键因素。

治疗费用高

使用处方药、诊断测试和外科手术持续治疗动脉粥状硬化是必要的。这些治疗为个人和家庭带来了巨大的费用。此外，为了应对心臟病和中风等副作用，住院、手术和復原的费用往往很高。许多动脉粥状硬化患者需要药物治疗来治疗疾病并降低併发症的风险。市场扩张受到这些疗法的成本和潜在使用期限的限制。

COVID-19 的影响：

COVID-19大流行对动脉粥状硬化药物市场产生了负面影响，因为几家参与资金筹措的公司推迟了针对该疾病的创新动脉粥样硬化药物的资金和投资。它影响了我。此外，疫情对正在进行的动脉粥状硬化临床试验产生了不利影响，导致临床试验延迟，并阻碍了动脉粥状硬化药物的全球市场扩张。

预计在预测期内，口服细分市场将是最大的

预计口腔细分市场在预测期内将是最大的。这是由于人们对常规胆固醇检测和治疗以及久坐生活方式的了解增加，这些生活方式与其他疾病（包括糖尿病）的发展有关。此外，黏膜渗透性、药物溶解度和胃肠道环境稳定性也是口服药物的优点。结果，需求扩大，有助于动脉硬化治疗药物市场占有率的扩大。

预计零售药局领域在预测期内年复合成长率最高

零售药房领域预计在预测期内年复合成长率最高。这与人们从药局和零售药局购买药品的愿望不断增加有关，因为这些药局可以提供廉价合理的药品，并且可以方便地获得心血管药物。另一个好处是，前往零售药局和药局购买动脉粥状硬化药物的顾客有了解处方笺的一切的优势，这推动了这一领域的成长。

比最大的地区

由于政府和私营部门倡导健康生活方式的配合措施不断增加，预计北美在预测期内将占据最大的市场占有率。由于医疗基础设施完善、购买力强劲以及动脉粥状硬化治疗产品的接受度不断提高，该市场预计将扩大。此外，该地区心血管疾病罹患率的上升和社会预防疾病意识的提高正在推动动脉硬化治疗的需求并支持市场扩张。

复合年复合成长率最高的地区：

预计亚太地区在预测期内将维持最高的年复合成长率。这是由于该地区製药公司的存在以及人口大国购买力的不断增强。由于患有各种心血管疾病的老年人数量不断增加，市场正在扩大。此外，由于其庞大的人口基数、未满足的医疗需求和不断增长的可支配所得，它具有巨大的成长潜力。此外，医疗旅游的扩张和医疗保健基础设施的成长正在创造一个盈利的市场。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球动脉硬化市场：依阶段

  • 斑块生长
  • 破坏斑块
  • 内皮损伤和免疫反应
  • 脂肪纹
  • 其他阶段

第6章全球动脉硬化市场：依治疗分类

  • 药品
    • β 受体阻断药
    • 血管张力素转换酶 (Ace) 抑制剂
    • 钙通道阻断剂
    • 抗血小板药物
    • 降低胆固醇药物
  • 外科手术
    • 纤溶疗法
    • 切除术
    • 冠状动脉绕道术
    • 血管成形术
  • 其他治疗方法

第7章全球动脉粥状硬化市场：依给药途径

  • 胃肠外的
  • 口服

第8章全球动脉粥状硬化市场：依配销通路

  • 零售药房
  • 网路药房

第9章全球动脉粥状硬化市场：依诊断

  • 多普勒超音波
  • 验血
  • 脚踝臂指数 (ABI)
  • 超音波心臟检查
  • 心电图（ECG）
  • 其他诊断

第10章全球动脉粥状硬化市场：依最终用户分类

  • 专科诊所
  • 居家护理
  • 医院
  • 其他最终用户

第11章全球动脉粥状硬化市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第12章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第13章公司简介

  • Boehringer Ingelheim International GmbH.
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer Inc.
  • Lupin
  • GlaxoSmithKline plc
  • Dr. Reddy's Laboratories Ltd.
  • Allergan
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Sanofi
  • Allergan
  • Eli Lilly and Company
  • AbbVie Inc.
  • Amgen Inc.
  • Gilead Sciences, Inc.
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Private Limited
  • AstraZeneca
  • Merck & Co., Inc.
  • Mylan NV
Product Code: SMRC23983

According to Stratistics MRC, the Global Atherosclerosis Market is growing at a CAGR of 4.24% during the forecast period. Atherosclerosis is the term used to describe the gradual hardening and construction of your arteries brought on by cholesterol plaques lining them. The use of medications to treat high blood pressure and high cholesterol will reduce, if not stop, atherosclerosis. They lessen your risk of experiencing a heart attack or stroke. Bypass surgery includes utilizing a vascular from another region of body or a synthetic tube to redirect blood around a blocked or constricted artery. To dissolve a blood clot, thrombolytic treatment involves injecting a drug into the affected artery. Atherectomy is the process of removing plaque from your arteries using a catheter with a cutting edge at one end.

According to the European Heart Network, cardiovascular disease affects 3.9 million people in Europe each year, with over 1.8 million people dying in the European Union.

Market Dynamics:

Driver:

Increasing prevalence of cardiovascular diseases

It is predicted that the market would develop faster due to the increased frequency of cardiovascular disorders worldwide. Sedentary lifestyles are to blame for the highest incidence of cardiovascular disease in developed nations. Additionally, a rise in the elderly population and a sedentary lifestyle that results in a high frequency of cardiovascular illnesses and growing awareness of available treatments is predicted to boost the market under study.

Restraint:

Side effects associated with atherosclerosis

The risk of cardiovascular events like heart attacks and strokes is increased by atherosclerosis. These occurrences may result in death or serious disability. Peripheral artery disease may be brought on by atherosclerosis in the arteries of the extremities, particularly the legs. This may result in discomfort, numbness, and trouble walking. This can put more stress on the cardiovascular system by making arteries less elastic and raising blood pressure. Growth of the market is anticipated to be hampered by the adverse effects of atherosclerosis and the low effectiveness.

Opportunity:

Increasing infrastructure spending for healthcare

The increase in healthcare spending, which aids in enhancing its infrastructure, is the element driving the market's growth rate. By boosting funds, a number of government agencies seek to enhance the healthcare infrastructure. Rising awareness-raising efforts by both governmental and private organizations, an increase in disposable income, and the high incidence of high blood pressure are other key elements that are projected to boost the market's growth rate throughout the course of the forecast year.

Threat:

High cost of treatment

The continuing treatment of atherosclerosis using prescription drugs, diagnostic exams, and surgical procedures is necessary. These medical treatments can be quite expensive for both individuals and families. Furthermore, the costs of hospitalization, surgery, and rehabilitation are frequently significant when addressing side effects including heart attacks and strokes. To treat their illness and lower the risk of complications, many people with atherosclerosis need medication. The market expansion is being constrained by the cost and potential duration of use of these treatments.

COVID-19 Impact:

The COVID-19 pandemic had a detrimental effect on the market for atherosclerosis medications since it delayed financing from several firms involved in research and development as well as investments in innovative atherosclerosis therapies that target the disease. Additionally, the pandemic had a detrimental effect on the atherosclerosis clinical studies that were in progress, which hampered the expansion of the worldwide market for atherosclerosis medications as a result of the delayed clinical trials.

The oral segment is expected to be the largest during the forecast period

The oral segment is expected to be the largest during the forecast period. This is due to a rise in knowledge about routine cholesterol testing and therapy as well as sedentary lifestyles that have been linked to the onset of other ailments, including diabetes. Additionally, the mucosal permeability, drug solubility, and environmental stability in the gastrointestinal tract are benefits of oral medications. As a result, their demand is larger, which helps the market share growth of medications for atherosclerosis.

The retail pharmacy segment is expected to have the highest CAGR during the forecast period

The retail pharmacy segment is expected to have the highest CAGR during the forecast period. This is linked to a growth in the desire for buying medications from drug shops and retail pharmacies owing to the availability of cheap and reasonably priced medications as well as the simplicity of obtaining cardiovascular medications in these pharmacies. Additionally, customers who visit retail pharmacies and drug shops to buy atherosclerosis meds benefit from the ability to learn all there is to know about the prescriptions, which serves to fuel the segment's expansion.

Region with largest share:

North America is projected to hold the largest market share during the forecast period due to increase in government and private sector efforts to promote healthy lifestyles. The market is anticipated to increase as a result of the well-established healthcare infrastructure, strong buying power, and rising acceptance of atherosclerosis treatment products. In addition, rising cardiovascular disease incidence in the area and increased public awareness of disease prevention are driving up demand for atherosclerosis medications and propelling the market's expansion.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. This is due to the presence of pharmaceutical businesses in the area as well as the increase in the purchasing power of populous nations. The market is expanding as a result of the growing number of elderly people who are suffering from different cardiovascular ailments. Additionally, because of the huge population base, unmet medical demands, and rise in disposable income, it has a great growth potential. Additionally, a profitable market is created by the expansion of medical tourism and growing healthcare infrastructure.

Key players in the market:

Some of the key players in Atherosclerosis Market include: Boehringer Ingelheim International GmbH., Bayer AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Lupin, GlaxoSmithKline plc, Dr. Reddy's Laboratories Ltd. , Allergan, F. Hoffmann-La Roche Ltd., Novartis AG, Bristol-Myers Squibb Company, Sanofi, Allergan, Eli Lilly and Company, AbbVie Inc., Amgen Inc., Gilead Sciences, Inc., Hikma Pharmaceuticals PLC, Johnson & Johnson Private Limited, AstraZeneca, Merck & Co., Inc. and Mylan N.V.

Key Developments:

In September 2022, Novo Nordisk has entered into a new strategic cooperation with Microsoft to accelerate medication research and development via the use of big data and artificial intelligence (AI). The team will employ artificial intelligence to construct models that can predict a person's risk of getting atherosclerosis or arterial plaque development.

In August 2022, AstraZeneca and Merck, known as MSD outside the United States and Canada, announced that the European Commission (EC) has approved LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations (gBRCAm) and HER2-negative high-risk early breast cancer who have previously received neoadjuvant or adjuvant chemotherapy.

In December 2021, Novartis announced the US Food and Drug Administration (FDA) approval of Leqvio, the first and only small interfering RNA (siRNA) therapy to lower low-density lipoprotein cholesterol with two doses a year, after an initial dose and one at three months.

Stages Covered:

  • Plaque Growth
  • Plaque Rupture
  • Endothelial Damage and Immune Response
  • Fatty Streak
  • Other Stages

Treatments Covered:

  • Medication
  • Surgery
  • Other Treatments

Route of Administrations Covered:

  • Parenteral
  • Oral

Distribution Channels Covered:

  • Retail Pharmacy
  • Online Pharmacy

Diagnosis Covered:

  • Doppler Ultrasound
  • Blood Tests
  • Ankle-brachial Index (ABI)
  • Echocardiogram
  • Electrocardiogram (ECG)
  • Other Diagnosis

End Users Covered:

  • Specialty Clinics
  • Homecare
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Atherosclerosis Market, By Stage

  • 5.1 Introduction
  • 5.2 Plaque Growth
  • 5.3 Plaque Rupture
  • 5.4 Endothelial Damage and Immune Response
  • 5.5 Fatty Streak
  • 5.6 Other Stages

6 Global Atherosclerosis Market, By Treatment

  • 6.1 Introduction
  • 6.2 Medication
    • 6.2.1 Beta Blockers
    • 6.2.2 Angiotensin-Converting Enzyme (Ace) Inhibitors
    • 6.2.3 Calcium Channel Blockers
    • 6.2.4 Anti-Platelet Drugs
    • 6.2.5 Cholesterol Lowering Medications
  • 6.3 Surgery
    • 6.3.1 Fibrinolytic therapy
    • 6.3.2 Endarterectomy
    • 6.3.3 Coronary artery bypass surgery
    • 6.3.4 Angioplasty
  • 6.4 Other Treatments

7 Global Atherosclerosis Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Parenteral
  • 7.3 Oral

8 Global Atherosclerosis Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Retail Pharmacy
  • 8.3 Online Pharmacy

9 Global Atherosclerosis Market, By Diagnosis

  • 9.1 Introduction
  • 9.2 Doppler Ultrasound
  • 9.3 Blood Tests
  • 9.4 Ankle-brachial Index (ABI)
  • 9.5 Echocardiogram
  • 9.6 Electrocardiogram (ECG)
  • 9.7 Other Diagnosis

10 Global Atherosclerosis Market, By End User

  • 10.1 Introduction
  • 10.2 Specialty Clinics
  • 10.3 Homecare
  • 10.4 Hospitals
  • 10.5 Other End Users

11 Global Atherosclerosis Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Boehringer Ingelheim International GmbH.
  • 13.2 Bayer AG
  • 13.3 Teva Pharmaceutical Industries Ltd.
  • 13.4 Pfizer Inc.
  • 13.5 Lupin
  • 13.6 GlaxoSmithKline plc
  • 13.7 Dr. Reddy's Laboratories Ltd.
  • 13.8 Allergan
  • 13.9 F. Hoffmann-La Roche Ltd.
  • 13.10 Novartis AG
  • 13.11 Bristol-Myers Squibb Company
  • 13.12 Sanofi
  • 13.13 Allergan
  • 13.14 Eli Lilly and Company
  • 13.15 AbbVie Inc.
  • 13.16 Amgen Inc.
  • 13.17 Gilead Sciences, Inc.
  • 13.18 Hikma Pharmaceuticals PLC
  • 13.19 Johnson & Johnson Private Limited
  • 13.20 AstraZeneca
  • 13.21 Merck & Co., Inc.
  • 13.22 Mylan N.V.

List of Tables

  • Table 1 Global Atherosclerosis Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Atherosclerosis Market Outlook, By Stage (2021-2030) ($MN)
  • Table 3 Global Atherosclerosis Market Outlook, By Plaque Growth (2021-2030) ($MN)
  • Table 4 Global Atherosclerosis Market Outlook, By Plaque Rupture (2021-2030) ($MN)
  • Table 5 Global Atherosclerosis Market Outlook, By Endothelial Damage and Immune Response (2021-2030) ($MN)
  • Table 6 Global Atherosclerosis Market Outlook, By Fatty Streak (2021-2030) ($MN)
  • Table 7 Global Atherosclerosis Market Outlook, By Other Stages (2021-2030) ($MN)
  • Table 8 Global Atherosclerosis Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 9 Global Atherosclerosis Market Outlook, By Medication (2021-2030) ($MN)
  • Table 10 Global Atherosclerosis Market Outlook, By Beta Blockers (2021-2030) ($MN)
  • Table 11 Global Atherosclerosis Market Outlook, By Angiotensin-Converting Enzyme (Ace) Inhibitors (2021-2030) ($MN)
  • Table 12 Global Atherosclerosis Market Outlook, By Calcium Channel Blockers (2021-2030) ($MN)
  • Table 13 Global Atherosclerosis Market Outlook, By Anti-Platelet Drugs (2021-2030) ($MN)
  • Table 14 Global Atherosclerosis Market Outlook, By Cholesterol Lowering Medications (2021-2030) ($MN)
  • Table 15 Global Atherosclerosis Market Outlook, By Surgery (2021-2030) ($MN)
  • Table 16 Global Atherosclerosis Market Outlook, By Fibrinolytic therapy (2021-2030) ($MN)
  • Table 17 Global Atherosclerosis Market Outlook, By Endarterectomy (2021-2030) ($MN)
  • Table 18 Global Atherosclerosis Market Outlook, By Coronary artery bypass surgery (2021-2030) ($MN)
  • Table 19 Global Atherosclerosis Market Outlook, By Angioplasty (2021-2030) ($MN)
  • Table 20 Global Atherosclerosis Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 21 Global Atherosclerosis Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 22 Global Atherosclerosis Market Outlook, By Parenteral (2021-2030) ($MN)
  • Table 23 Global Atherosclerosis Market Outlook, By Oral (2021-2030) ($MN)
  • Table 24 Global Atherosclerosis Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 25 Global Atherosclerosis Market Outlook, By Retail Pharmacy (2021-2030) ($MN)
  • Table 26 Global Atherosclerosis Market Outlook, By Online Pharmacy (2021-2030) ($MN)
  • Table 27 Global Atherosclerosis Market Outlook, By Diagnosis (2021-2030) ($MN)
  • Table 28 Global Atherosclerosis Market Outlook, By Doppler Ultrasound (2021-2030) ($MN)
  • Table 29 Global Atherosclerosis Market Outlook, By Blood Tests (2021-2030) ($MN)
  • Table 30 Global Atherosclerosis Market Outlook, By Ankle-brachial Index (ABI) (2021-2030) ($MN)
  • Table 31 Global Atherosclerosis Market Outlook, By Echocardiogram (2021-2030) ($MN)
  • Table 32 Global Atherosclerosis Market Outlook, By Electrocardiogram (ECG) (2021-2030) ($MN)
  • Table 33 Global Atherosclerosis Market Outlook, By Other Diagnosis (2021-2030) ($MN)
  • Table 34 Global Atherosclerosis Market Outlook, By End User (2021-2030) ($MN)
  • Table 35 Global Atherosclerosis Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 36 Global Atherosclerosis Market Outlook, By Homecare (2021-2030) ($MN)
  • Table 37 Global Atherosclerosis Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 38 Global Atherosclerosis Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.